Pro-Dex Inc. Common Stock (PDEX)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Pro-Dex traded at $62.27, with a FairStock P/E of 15.11 and P/B of 4.17. That is not an outrageous multiple for a medical supplier, but Graham would balk: the Graham Number is $37.23, leaving a margin of safety of -67.26%, so the price is far above asset-and-earnings value. The business is better than average. In fiscal FY2026 ended 2026-06-30, revenue was $77.5M and net income $13.7M, or diluted EPS $4.12, up from FY2025 revenue $66.6M and net income $9.0M, and FY2024 revenue $53.8M and net income $2.1M. Fiscal Q3 2026, the quarter ended 2026-03-31, had $19.9M revenue and $3.9M net income. FairStock lists revenue growth of 16.64% and profit growth of 138.68%. ROE is 32.43%, ROCE 11.97%, and D/E 0.40; Altman Z 6.43 suggests low bankruptcy risk, while Piotroski 6/9 is decent, not flawless. The moat is modest: switching costs in regulated surgical instruments help, but 201 employees and a $199.5M market cap mean limited scale. Free cash flow was $6.8M, only a 3.4% FCF yield, so cash generation lags accounting profits. FairStock PEG of 0.11 is alluring if growth persists, and beta 0.06 is unusually low. FairStock classifies it as a STALWART, with 17.2% annual profit growth and 15.3% revenue growth over five years. I like the business, but at this price I want a larger discount.

In plain English: Pro-Dex makes specialized powered surgical tools for medical device companies. Its sales and profits have grown quickly, and the company carries manageable debt. But at $62.27 on 2026-10-13, the stock looks expensive compared with its profits and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer